Your request to link to rcsb for Integrase
- 1HYV: hiv integrase core domain complexed with tetraphenyl arsonium (10.1107/S0907444901001652 )
- 1HYZ: hiv integrase core domain complexed with a derivative of tetraphenyl arsonium. (10.1107/S0907444901001652 )
- 1IHV: solution structure of the dna binding domain of hiv-1 integrase, nmr, minimized average structure (10.1021/BI00031A002 )
- 1IHW: solution structure of the dna binding domain of hiv-1 integrase, nmr, 40 structures (10.1021/BI00031A002 )
- 1K6Y: crystal structure of a two-domain fragment of hiv-1 integrase (10.1093/EMBOJ/20.24.7333 )
- 1QMC: c-terminal dna-binding domain of hiv-1 integrase, nmr, 42 structures
- 1QS4: core domain of hiv-1 integrase complexed with mg++ and 1-(5- chloroindol-3-yl)-3-hydroxy-3-(2h-tetrazol-5-yl)-propenone (10.1073/PNAS.96.23.13040 )
- 1WJB: solution structure of the n-terminal zn binding domain of hiv-1 integrase (d form), nmr, 40 structures (10.1038/NSB0797-567 )
- 1WJD: solution structure of the n-terminal zn binding domain of hiv-1 integrase (e form), nmr, 38 structures (10.1038/NSB0797-567 )
- 1WJF: solution structure of h12c mutant of the n-terminal zn binding domain of hiv-1 integrase complexed to cadmium, nmr, 40 structures
- 2B4J: structural basis for the recognition between hiv-1 integrase and ledgf/p75 (10.1073/PNAS.0506924102 )
- 2ITG: catalytic domain of hiv-1 integrase: ordered active site in the f185h construct (10.1016/S0014-5793(96)01236-7 )
- 3AO1: fragment-based approach to the design of ligands targeting a novel site in hiv-1 integrase (10.1002/CMDC.201000483 )
- 3AO2: fragment-based approach to the design of ligands targeting a novel site on hiv-1 integrase (10.1002/CMDC.201000483 )
- 3AO3: fragment-based approach to the design of ligands targeting a novel site on hiv-1 integrase (10.1002/CMDC.201000483 )
- 3AO4: fragment-based approach to the design of ligands targeting a novel site on hiv-1 integrase (10.1002/CMDC.201000483 )
- 3AO5: fragment-based approach to the design of ligands targeting a novel site on hiv-1 integrase (10.1002/CMDC.201000483 )
- 3AV9: crystal structures of novel allosteric peptide inhibitors of hiv integrase in the ledgf binding site (10.1002/CBIC.201100350 )
- 3AVA: crystal structures of novel allosteric peptide inhibitors of hiv integrase in the ledgf binding site (10.1002/CBIC.201100350 )
- 3AVB: crystal structures of novel allosteric peptide inhibitors of hiv integrase in the ledgf binding site (10.1002/CBIC.201100350 )
- 3AVC: crystal structures of novel allosteric peptide inhibitors of hiv integrase in the ledgf binding site (10.1002/CBIC.201100350 )
- 3AVF: crystal structures of novel allosteric peptide inhibitors of hiv integrase in the ledgf binding site (10.1002/CBIC.201100350 )
- 3AVG: crystal structures of novel allosteric peptide inhibitors of hiv integrase in the ledgf binding site (10.1002/CBIC.201100350 )
- 3AVH: crystal structures of novel allosteric peptide inhibitors of hiv integrase in the ledgf binding site (10.1002/CBIC.201100350 )
- 3AVI: crystal structures of novel allosteric peptide inhibitors of hiv integrase in the ledgf binding site (10.1002/CBIC.201100350 )
- 3AVJ: crystal structures of novel allosteric peptide inhibitors of hiv integrase in the ledgf binding site (10.1002/CBIC.201100350 )
- 3AVK: crystal structures of novel allosteric peptide inhibitors of hiv integrase in the ledgf binding site (10.1002/CBIC.201100350 )
- 3AVL: crystal structures of novel allosteric peptide inhibitors of hiv integrase in the ledgf binding site (10.1002/CBIC.201100350 )
- 3AVM: crystal structures of novel allosteric peptide inhibitors of hiv integrase in the ledgf binding site (10.1002/CBIC.201100350 )
- 3AVN: crystal structures of novel allosteric peptide inhibitors of hiv integrase in the ledgf binding site (10.1002/CBIC.201100350 )
- 3L3U: crystal structure of the hiv-1 integrase core domain to 1.4a (10.1016/J.FEBSLET.2010.03.016 )
- 3L3V: structure of hiv-1 integrase core domain in complex with sucrose (10.1016/J.FEBSLET.2010.03.016 )
- 3LPT: hiv integrase (10.1038/NCHEMBIO.370 )
- 3LPU: hiv integrase (10.1038/NCHEMBIO.370 )
- 3NF6: structural basis for a new mechanism of inhibition of hiv integrase identified by fragment screening and structure based design (10.3851/IMP1716 )
- 3NF7: structural basis for a new mechanism of inhibition of hiv integrase identified by fragment screening and structure based design (10.3851/IMP1716 )
- 3NF8: structural basis for a new mechanism of inhibition of hiv integrase identified by fragment screening and structure based design (10.3851/IMP1716 )
- 3NF9: structural basis for a new mechanism of inhibition of hiv integrase identified by fragment screening and structure based design (10.3851/IMP1716 )
- 3NFA: structural basis for a new mechanism of inhibition of hiv integrase identified by fragment screening and structure based design (10.3851/IMP1716 )
- 3OVN: fragment-based approach to the design of ligands targeting a novel site on hiv-1 integrase (10.1002/CMDC.201000483 )
- 3VQ4: fragments bound to hiv-1 integrase (10.1177/1087057112465979 )
- 3VQ5: hiv-1 in core domain in complex with n-methyl-1-(4-methyl-2-phenyl-1, 3-thiazol-5-yl)methanamine (10.1177/1087057112465979 )
- 3VQ6: hiv-1 in core domain in complex with (1-methyl-5-phenyl-1h-pyrazol-4- yl)methanol (10.1177/1087057112465979 )
- 3VQ7: hiv-1 in core domain in complex with 4-(1h-pyrrol-1-yl)aniline (10.1177/1087057112465979 )
- 3VQ8: hiv-1 in core domain in complex with (3r)-3,4-dihydro-2h-chromen-3- ylmethanol (10.1177/1087057112465979 )
- 3VQ9: hiv-1 in core domain in complex with 6-fluoro-1,3-benzothiazol-2-amine (10.1177/1087057112465979 )
- 3VQA: hiv-1 in core domain in complex with 1-benzothiophen-6-amine 1,1- dioxide (10.1177/1087057112465979 )
- 3VQB: hiv-1 in core domain in complex with 6-fluoro-4h-1,3-benzodioxine-8- carboxylic acid (10.1177/1087057112465979 )
- 3VQC: hiv-1 in core domain in complex with (5-methyl-3-phenyl-1,2-oxazol-4- yl)methanol (10.1177/1087057112465979 )
- 3VQD: hiv-1 in core domain in complex with 5-methyl-3-phenyl-1,2-oxazole-4- carboxylic acid (10.1177/1087057112465979 )
- 3VQE: hiv-1 in core domain in complex with [1-(4-fluorophenyl)-5-methyl-1h- pyrazol-4-yl]methanol (10.1177/1087057112465979 )
- 3VQP: hiv-1 in core domain in complex with 2,3-dihydro-1,4-benzodioxin-5- ylmethanol (10.1177/1087057112465979 )
- 3VQQ: hiv-1 integrase core domain in complex with 2,1,3-benzothiadiazol-4- amine (10.1177/1087057112465979 )
- 3WNE: cyclic hexapeptide pkidng in complex with hiv-1 integrase
- 3WNF: cyclic hexapeptide ckidnc in complex with hiv-1 integrase
- 3WNG: cyclic hexapeptide pkidnp in complex with hiv-1 integrase
- 3WNH: cyclic hexapeptide pkzdnv in complex with hiv-1 integrase
- 3ZCM: small molecule inhibitors of the ledgf site of hiv integrase identified by fragment screening and structure based design. (10.1371/JOURNAL.PONE.0040147 )
- 3ZSO: small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based design (10.1371/JOURNAL.PONE.0040147 )
- 3ZSQ: small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design (10.1371/JOURNAL.PONE.0040147 )
- 3ZSR: small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design (10.1371/JOURNAL.PONE.0040147 )
- 3ZSV: small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design (10.1371/JOURNAL.PONE.0040147 )
- 3ZSW: small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design (10.1371/JOURNAL.PONE.0040147 )
- 3ZSX: small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design (10.1371/JOURNAL.PONE.0040147 )
- 3ZSY: small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design (10.1371/JOURNAL.PONE.0040147 )
- 3ZSZ: small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design (10.1371/JOURNAL.PONE.0040147 )
- 3ZT0: small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design (10.1371/JOURNAL.PONE.0040147 )
- 3ZT1: small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design (10.1371/JOURNAL.PONE.0040147 )
- 3ZT2: small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design (10.1371/JOURNAL.PONE.0040147 )
- 3ZT3: small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design (10.1371/JOURNAL.PONE.0040147 )
- 3ZT4: small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design (10.1371/JOURNAL.PONE.0040147 )
- 4AH9: parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification (10.1177/1087057112465979 )
- 4AHR: parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification (10.1177/1087057112465979 )
- 4AHS: parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification (10.1177/1087057112465979 )
- 4AHT: parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification (10.1177/1087057112465979 )
- 4AHU: parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification (10.1177/1087057112465979 )
- 4AHV: parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification (10.1177/1087057112465979 )
- 4CE9: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CEA: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CEB: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CEC: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CED: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CEE: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CEF: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CEO: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CEQ: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CER: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CES: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CEZ: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CF0: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CF1: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CF2: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CF8: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CF9: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CFA: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CFB: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CFC: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CFD: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CGD: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CGF: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CGG: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CGH: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CGI: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CGJ: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CHN: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CHO: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CHP: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CHQ: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CHY: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CHZ: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CIE: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CIF: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CIG: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CJ3: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CJ4: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CJ5: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CJE: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CJF: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CJK: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CJL: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CJP: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CJQ: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CJR: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CJS: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CJT: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CJU: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CJV: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CJW: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CK1: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CK2: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4CK3: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4DMN: hiv-1 integrase catalytical core domain (10.1074/JBC.M112.354373 )
- 4E1M: crystal structure of hiv-1 integrase with a non-catayltic site inhibitor (10.1074/JBC.M112.347534 )
- 4E1N: crystal structure of hiv-1 integrase with a non-catayltic site inhibitor (10.1074/JBC.M112.347534 )
- 4GVM: hiv-1 integrase catalytic core domain a128t mutant complexed with allosteric inhibitor (10.1074/JBC.M112.443390 )
- 4GW6: hiv-1 integrase catalytic core domain complexed with allosteric inhibitor (10.1074/JBC.M112.443390 )
- 4ID1: hiv-1 integrase catalytic core domain complexed with allosteric inhibitor (10.1073/PNAS.1300703110 )
- 4JLH: hiv-1 integrase catalytic core domain a128t mutant complexed with allosteric inhibitor (10.1074/JBC.M112.443390 )
- 4LH4: dual inhibition of hiv-1 replication by integrase-ledgf allosteric inhibitors is predominant at post-integration stage during virus production rather than at integration (10.1186/1742-4690-10-144 )
- 4LH5: dual inhibition of hiv-1 replication by integrase-ledgf allosteric inhibitors is predominant at post-integration stage during virus production rather than at integration (10.1186/1742-4690-10-144 )
- 4NYF: hiv integrase in complex with inhibitor (10.1021/ML500002N )
- 4O0J: hiv-1 integrase catalytic core domain complexed with allosteric inhibitor (2s)-tert-butoxy[4-(4-chlorophenyl)-6-(3,4-dimethylphenyl)- 2,5-dimethylpyridin-3-yl]ethanoic acid (10.1371/JOURNAL.PPAT.1004171 )
- 4O55: hiv-1 integrase catalytic core domain complexed with allosteric inhibitor (2s)-tert-butoxy[6-(5-chloro-1h-benzimidazol-2-yl)-2,5- dimethyl-4-phenylpyridin-3-yl]ethanoic acid (10.1371/JOURNAL.PPAT.1004171 )
- 4O5B: hiv-1 integrase catalytic core domain complexed with allosteric inhibitor (2s)-tert-butoxy[6-(5-chloro-1h-benzimidazol-2-yl)-2,5- dimethyl-4-phenylpyridin-3-yl]ethanoic acid (10.1371/JOURNAL.PPAT.1004171 )
- 4OJR: crystal structure of the hiv-1 integrase catalytic domain with gsk1264 (10.1074/JBC.M114.551119 )
- 4OVL: interrogating hiv integrase for compounds that bind- a sampl challenge (10.1007/S10822-014-9721-7 )
- 4TSX: hiv-1 integrase catalytic core domain mutant complexed with allosteric inhibitor (10.1186/S12977-014-0100-1 )
- 4Y1C: cyclic hexapeptide cyc[ndpoppkid] in complex with hiv-1 integrase core domain
- 4Y1D: cyclic hexapeptide cyc[ndpoppkid] in complex with hiv-1 integrase core domain
- 5EU7: crystal structure of hiv-1 integrase catalytic core in complex with fab (10.1016/J.STR.2016.08.015 )
- 5HOT: structural basis for inhibitor-induced aggregation of hiv-1 integrase (10.1371/JOURNAL.PBIO.1002584 )
- 5HRN: hiv integrase catalytic domain containing f185k mutation complexed with gsk0002 (10.1371/JOURNAL.PBIO.1002584 )
- 5HRP: hiv integrase catalytic domain containing f185k + a124t mutations complexed with gsk0002 (10.1371/JOURNAL.PBIO.1002584 )
- 5HRR: hiv integrase catalytic domain containing f185k + a124n + t125s mutations complexed with gsk0002 (10.1371/JOURNAL.PBIO.1002584 )
- 5HRS: hiv integrase catalytic domain containing f185k + a124n + t125a mutations complexed with gsk0002 (10.1371/JOURNAL.PBIO.1002584 )
- 5JL4: inhibitor resistant mutant catalytic core domain of hiv-1 integrase (10.1074/JBC.M117.816645 )
- 5KGW: hiv1 catalytic core domain in complex with inhibitor: (2~{s})-2-[3-(3, 4-dihydro-2~{h}-chromen-6-yl)-1-methyl-indol-2-yl]-2-[(2- methylpropan-2-yl)oxy]ethanoic acid (10.1016/J.BMCL.2016.08.037 )
- 5KGX: hiv1 catalytic core domain in complex with an inhibitor (2~{s})-2-[3- (3,4-dihydro-2~{h}-chromen-6-yl)-1-methyl-indol-2-yl]-2-[(2- methylpropan-2-yl)oxy]ethanoic acid (10.1016/J.BMCL.2016.08.037 )
- 5KRS: hiv-1 integrase catalytic core domain in complex with an allosteric inhibitor, 3-(1h-pyrrol-1-yl)-2-thiophenecarboxylic acid (10.1074/JBC.M116.753384 )
- 5KRT: hiv-1 integrase catalytic core domain (ccd) in complex with a fragment-derived allosteric inhibitor (10.1074/JBC.M116.753384 )
- 5OI2: dissociation of biochemical and antiretroviral activities of integrase-ledgf allosteric inhibitors revealed by resistance of a125 polymorphic hiv-1 (10.1074/JBC.M117.816793 )
- 5OI3: dissociation of biochemical and antiretroviral activities of integrase-ledgf allosteric inhibitors revealed by resistance of a125 polymorphic hiv-1 (10.1074/JBC.M117.816793 )
- 5OI5: dissociation of biochemical and antiretroviral activities of integrase-ledgf allosteric inhibitors revealed by resistance of a125 polymorphic hiv-1 (10.1074/JBC.M117.816793 )
- 5OI8: dissociation of biochemical and antiretroviral activities of integrase-ledgf allosteric inhibitors revealed by resistance of a125 polymorphic hiv-1 (10.1074/JBC.M117.816793 )
- 5OIA: dissociation of biochemical and antiretroviral activities of integrase-ledgf allosteric inhibitors revealed by resistance of a125 polymorphic hiv-1 (10.1074/JBC.M117.816793 )
- 5TC2: c-terminal domain of hiv-1 integrase, crystal structure
- 5U1C: structure of tetrameric hiv-1 strand transfer complex intasome (10.1126/SCIENCE.AAH5163 )
- 6EB1: hiv-1 integrase catalytic core domain complexed with allosteric inhibitor (2s)-tert-butoxy[3-(3,4-dihydro-2h-1-benzopyran-6-yl)-1- phenylisoquinolin-4-yl]acetic acid (10.1021/ACSMEDCHEMLETT.8B00633 )
- 6EB2: hiv-1 integrase catalytic core domain complexed with allosteric inhibitor (2s)-[1-(1-benzyl-1h-pyrazol-4-yl)-3-(3,4-dihydro-2h-1- benzopyran-6-yl)isoquinolin-4-yl](tert-butoxy)acetic acid (10.1021/ACSMEDCHEMLETT.8B00633 )
- 6EX9: crystal structure of hiv-1 integrase catalytic core domain with inhibitor peptide (10.1101/301721 )
- 6JCF: cryogenic structure of hiv-1 integrase catalytic core domain by synchrotron (10.3390/IJMS20081943 )
- 6JCG: room temperature structure of hiv-1 integrase catalytic core domain by serial femtosecond crystallography. (10.3390/IJMS20081943 )
- 6L0C: crystal structure of hiv-1 integrase catalytic core domain (a128t/k173q/f185k) (10.1128/JVI.00486-20 )
- 6LMI: crystal structure of hiv-1 integrase catalytic core domain in complex with 2-(tert-butoxy)-2-[3-(3,4-dihydro-2h-1-benzopyran-6-yl)-6- methanesulfonamido-2,3',4',5-tetramethyl-[1,1'-biphenyl]-4-yl]acetic acid (10.1016/J.BMC.2020.115643 )
- 6LMQ: crystal structure of hiv-1 integrase catalytic core domain in complex with 2-(tert-butoxy)-2-[3-(3,4-dihydro-2h-1,4-benzoxazin-6-yl)-6- methanesulfonamido-2,3',4',5-tetramethyl-[1,1'-biphenyl]-4-yl]acetic acid (10.1016/J.BMC.2020.115643 )
- 6NCJ: structure of hiv-1 integrase with potent 5,6,7,8-tetrahydro-1,6- naphthyridine derivatives allosteric site inhibitors (10.1021/ACS.JMEDCHEM.8B01473 )
- 6NUJ: hiv-1 integrase catalytic core domain complexed with allosteric inhibitor bi-224436 (10.7554/ELIFE.46344 )
- 6PUT: structure of hiv cleaved synaptic complex (csc) intasome bound with calcium (10.1126/SCIENCE.AAY8015 )
- 6PUW: structure of hiv cleaved synaptic complex (csc) intasome bound with magnesium and bictegravir (bic) (10.1126/SCIENCE.AAY8015 )
- 6PUY: structure of hiv cleaved synaptic complex (csc) intasome bound with magnesium and insti xz426 (compound 4d) (10.1126/SCIENCE.AAY8015 )
- 6PUZ: structure of hiv cleaved synaptic complex (csc) intasome bound with magnesium and insti xz446 (compound 4f) (10.1126/SCIENCE.AAY8015 )
- 6T6E: crystal structure of the c-terminal domain of the hiv-1 integrase (pnl4-3) (10.1128/JVI.01035-20 )
- 6T6I: crystal structure of the c-terminal domain of the hiv-1 integrase (subtype a2) (10.1128/JVI.01035-20 )
- 6T6J: crystal structure of the c-terminal domain of the hiv-1 integrase (subtype a2, mutant n254k, k340q) (10.1128/JVI.01035-20 )
- 6U8Q: cryoem structure of hiv-1 cleaved synaptic complex (csc) intasome (10.1016/J.JMB.2020.01.040 )
- 6UM8: hiv integrase in complex with compound-14 (10.1021/ACS.JMEDCHEM.9B01681 )
- 6V3K: structure of hiv cleaved synaptic complex (csc) intasome bound with magnesium and insti xz419 (compound 4c) (10.1126/SCIENCE.AAY8015 )
- 6VDK: cryoem structure of hiv-1 conserved intasome core (10.1016/J.JMB.2020.01.040 )
- 6VKA: hiv integrase core domain (in) in complex with dimer-spanning ligand
- 6VLH: hiv integrase core domain (in) in complex with dimer-spanning ligand
- 6VLM: core catalytic domain of hiv integrase in complex with virtual screening hit (10.1021/ACS.JCIM.0C00113 )
- 6VQS: hiv integrase core domain (in) in complex with [5-(3-fluorophenyl)-1- benzofuran-3-yl]acetic acid
- 6VRG: structure of hiv-1 integrase with native amino-terminal sequence (10.1186/S12977-020-00537-X )
- 6VX2: hiv integrase core domain in complex with inhibitor (5-methyl-1- benzofuran-3-yl)acetic acid
- 6W0U: hiv integrase core domain in complex with inhibitor 2-(2-ethynyl-5- methyl-1-benzofuran-3-yl)acetic acid
- 6W42: hiv integrase core domain in complex with inhibitor 2-(5-methyl-2-(2- (thiophen-2-yl)ethynyl)-1-benzofuran-3-yl)acetic acid
- 6WC8: hiv integrase core domain in complex with inhibitor 2-(5-(3- fluorophenyl)-2-(2-(thiophen-2-yl)ethynyl)-1- benzofuran-3-yl) ethanoic acid
- 6WE7: hiv integrase core domain in complex with inhibitor 3-methyl-2-{5- methyl-2-[2-(thiophen-2-yl)ethynyl]-1- benzofuran-3-yl}butanoic acid
- 7D83: crystal structure of hiv-1 integrase catalytic core domain in complex with 2-(tert-butoxy)-2-(2-(3-cyclohexylureido)-3,6-dimethyl-5-(5- methylchroman-6-yl)pyridin-4-yl)acetic acid (10.1016/J.BMCL.2020.127742 )
- 7KE0: hiv-1 integrase catalytic core domain complexed with allosteric inhibitor stp03-0404
- 7L1P: hiv integrase core domain (in) in complex with dimer-spanning ligand
- 7L23: hiv integrase core domain in complex with inhibitor 2-(5-(3- fluorophenyl)-2-(2-(thiophen-2-yl)ethynyl)-1- benzofuran-3-yl) ethanoic acid
- 7LQP: rapid development of potent inhibitors of the hiv integrase-ledgf interaction by fragment-linking using off-rate screening
- 7T9H: hiv integrase in complex with compound-15 (10.1021/ACS.JMEDCHEM.1C02169 )
- 7T9O: hiv integrase in complex with compound-25 (10.1021/ACS.JMEDCHEM.1C02169 )
- 7U2U: crystal structure of hiv-1 integrase complexed with compound-2a aka (2s)-2-(tert-butoxy)-2-[7-(4,4-dimethylpipe ridin-1-yl)-8-{4-[2-(4- fluorophenyl)ethoxy]phenyl}-2,5-dim ethylimidazo[1,2-a]pyridin-6- yl]acetic acid (10.1016/J.BMC.2022.116833 )
- 7UOQ: crystal structure of hiv-1 integrase complexed with (2s)-2-(tert- butoxy)-2-(5-{2-[(2-chloro-6-m ethylphenyl)methyl]-1,2,3,4- tetrahydroisoquinolin-6-yl}-4- (4,4-dimethylpiperidin-1-yl)-2- methylpyridin-3-yl)acetic acid (10.1021/ACSMEDCHEMLETT.2C00115 )